Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months

Molecular Genetics and Metabolism

Volumn 97, Issue 4, 2009, Pages 278-283

  Barr, Caroline ^a   Clarke, Joe T R ^a   Ntwari, Aimé ^a   Drouin, Régen ^a   Auray Blais, Christiane ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Biomarker; CTH; Fabry disease; Gb3; Gb3 creatinine; GL 3; Globotriaosylceramide; LC MS MS; Liquid chromatography tandem mass spectrometry; Screening; Urine filter paper sample

Indexed keywords

BIOLOGICAL MARKER; CREATININE; GLOBOTRIAOSYLCERAMIDE;

ARTICLE; CREATININE URINE LEVEL; FABRY DISEASE; FEMALE; FILTER; HUMAN; HUMAN EXPERIMENT; INFANT; LIQUID CHROMATOGRAPHY; MALE; NEWBORN; NORMAL HUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; TANDEM MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION;

EID: 67649668920     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.04.009     Document Type: Article

References (30)

1. Desnick R.J., Dawson G., Desnick S.J., Sweeley C.C., and Krivit W. Diagnosis of glycosphingolipidoses by urinary-sediment analysis. N. Engl. J. Med. 284 (1971) 739-744
2. Clarke J.T.R. Narrative review: Fabry disease. Ann. Intern. Med. 146 (2007) 425-433
3. Vedder A.C., Strijland A., vd Bergh Weerman M.A., Florquin S., Aerts J.M.F.G., and Hollak C.E.M. Manifestations of Fabry disease in placental tissue. J. Inherit. Metab. Dis. 29 (2006) 106-111
4. Desnick R.J. Prenatal diagnosis of Fabry disease. Prenat. Diagn. 27 (2007) 693-694
5. Zarate Y.A., and Hopkin R.J. Fabry's disease. Lancet 372 (2008) 1427-1435
6. Wraith J.E., Tylki-Szymanska A., Guffon N., Lien Y.H., Tsimaratos M., Vellodi A., and Germain D.P. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J. Pediatr. 152 (2008) 563-570
7. Hopkin R.J., Bissler J., Banikazemi M., Clarke L., Eng C.M., Germain D.P., Lemay R., Tylki-Szymanska A., and Wilcox W.R. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr. Res. 64 (2008) 550-555
8. Mehta A., and Widmer U. Natural history of Fabry disease. In: Mehta A., Beck M., and Sunder-Plassmann G. (Eds). Fabry Disease. Perspectives from 5 Years of FOS vol. 423 (2006), Oxford PharmaGenesis Ltd.
9. Schiffmann R., Rapkiewicz A., Abu-Asab M., Ries M., Askari H., Tsokos M., and Quezado M. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 448 (2006) 337-343
10. Moore D.F., Altarescu G., Ling G.S.F., Jeffries N., Frei K.P., Weibel T., Charria-Ortiz G., Ferri R., Arai A.E., Brady R.O., and Schiffmann R. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33 (2002) 525-531
11. Schiffmann R., and Ries M. Fabry's disease - an important risk factor for stroke. Lancet 366 (2005) 1754-1756
12. Eng C.M., Fletcher J., Wilcox W.R., Waldek S., Scott C.R., Sillence D.O., Breunig E., Charrow J., Germain D.P., Nicholls K., and Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J. Inherit. Metab. Dis. 30 (2007) 184-192
13. Ries M., Clarke J.T.R., Whybra C., Timmons M., Robinson C., Schlaggar B.L., Pastores G., Lien Y.H., Kampmann C., Brady R.O., Beck M., and Schiffmann R. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118 (2006) 924-932
14. Germain D.P., Waldek S., Banikazemi M., Bushinsky D.A., Charrow J., Desnick R.J., Lee P., Loew T., Vedder A.C., Abichandani R., Wilcox W.R., and Guffon N. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 18 (2007) 1547-1557
15. Lidove O., Joly D., Barbey F., Bekri S., Alexandra J.-F., Peigne V., Jaussaud R., and Papo T. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int. J. Clin. Pract. 61 (2007) 293-302
16. Banikazemi M., Bultas J., Waldek S., Wilcox W.R., Whitley C.B., McDonald M., Finkel R., Packman S., Bichet D.G., Warnock D.G., and Desnick R.J. Agalsidase-beta therapy for advanced Fabry disease. Ann. Intern. Med. 146 (2007) 76-86
17. Auray-Blais C., Cyr D., Mills K., Giguère R., and Drouin R. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J. Inherit. Metab. Dis. 30 (2007) 106
18. Auray-Blais C., Cyr D., Ntwari A., West M.L., Cox-Brinkman J., Bichet D.G., Germain D.P., Laframboise R., Melançon S.B., Stockley T., Clarke J.T.R., and Drouin R. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol. Genet. Metab. 93 (2008) 331-340
19. Auray-Blais C., Cyr D., and Drouin R. Quebec neonatal mass urinary screening programme: from micromolecules to macromolecules. J. Inherit. Metab. Dis. 30 (2007) 515-521
20. Auray-Blais C., Millington D.S., Young S.P., Clarke J.T.R., and Schiffmann R. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease. J. Inherit. Metab. Dis. 32 (2009) 303-308
21. Froissart R., Guffon N., Vanier M.T., Desnick R.J., and Maire I. Fabry disease: D313Y is an α-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol. Genet. Metab. 80 (2003) 307-314
22. Auray-Blais C., Giguère R., and Lemieux B. Newborn urine screening programme in the province of Quebec: an update of 30 years' experience. J. Inherit. Metab. Dis. 26 (2003) 393-402
23. Dukker A., and Guignard J.-P. Renal aspects of the term and preterm infant: a selective update. Curr. Opin. Pediar. 14 (2002) 175-182
24. 3 (globotriaosylceramide, CTH, GL3). Mol. Genet. Metab. 97 (2009) 91
25. Mills K., Morris P., Lee P., Vellodi A., Waldek S., Young E., and Winchester B. Measurement of urinary CDH ant CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J. Inherit. Metab. Dis. 28 (2005) 35-48
26. Whitfield P.D., Calvin J., Hogg S., O'Driscoll E., Halsall D., Burling K., Maguire G., Wright N., Cox T.M., Meikle P.J., and Deegan P.B. Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 28 (2005) 21-33
27. Guignard J.-P., and Drukker A. Why do newborn infants have a high plasma creatinine?. Pediatrics 103 (1999) e49-e55
28. Balfour-Lynn I. Newborn screening for cystic fibrosis: evidence for benefit. BMJ 93 (2008) 7-10
29. Mehta A. Fabry disease - Whom to treat and when?. Clin. Ther. 30 (2008) S43-S44
30. Gibas A.L., Klatt R., Johnson J., Clarke J.T.R., and Katz J. Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease. J. Genet. Couns. 17 (2008) 528-537